| (Values in U.S. Thousands) | Dec, 2019 | Dec, 2018 | Dec, 2017 | Dec, 2016 | Dec, 2015 |
| Sales | 23,870 | 75,590 | 138,880 | 109,620 | 89,650 |
| Sales Growth | -68.42% | -45.57% | +26.69% | +22.28% | +71.58% |
| Net Income | -290,060 | -176,060 | -88,100 | -21,000 | -83,310 |
| Net Income Growth | -64.75% | -99.84% | -319.52% | +74.79% | +15.51% |
Momenta Pharma (MNTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Momenta Pharmaceuticals is a leader in the analysis, characterization and design of complex pharmaceutical products. Their scientific foundation is a set of tools and methods that allow them to develop a deep understanding of the links between a compound's chemical structure, biological function and its manufacturing process. They are applying their innovative technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
Fiscal Year End Date: 12/31